Skip to main content

Cardio/Pulmonary

Clinical Trial Boom or Bust in Severe COVID-19

Oct 20, 2020

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.



Remdesivir

Read Article
Swedish population studied CV risk, studied gout. Among 22,057, 910 (4.1%) developed incident gout by 27.5 yrs w/ 5 Clusters: C1 no/few comorb; C2 had CKD; C3 CV dz; C4 obesity, dyslipidemia; C5 DM, HTN, diuretics.

Dr. John Cush RheumNow ( View Tweet)

Oct 20, 2020

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Oct 15, 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
EUSTAR study of ILD in systemic sclerosis: 826 pts with SSc-ILD finds 27% with progressive ILD (mod-severe FVC decline >5-10%) over 12 mos. Predictive factors for FVC decline over 5 yrs were male sex, higher mRSS skin score and reflux/dysphagia symptoms.

Dr. John Cush RheumNow ( View Tweet)

Oct 15, 2020

COVID Transmission from Young to Old

Oct 13, 2020

The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots. Among 767 hotspot counties identified during June and July 2020, early increases in the percent positivity among persons aged ≤24 years were

Read Article

Tofacitinib and Thromboembolic Risk

Oct 13, 2020

Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (

Read Article
Study of 196 RA pts shows lung Dz common by chest CT, regardless of serostatus. RA lung=higher mortality (HR of 5.3). RA lung dz found in 28%; 16% had ILD, 14% bronchiectasis, 9.5% w pleural dz.

Dr. John Cush RheumNow ( View Tweet)

Oct 12, 2020

Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity

Oct 11, 2020

A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA)  and that risk is linked to RA disease activity. 

Read Article

Systemic Steroids Reduce Mortality in COVID-19

Oct 06, 2020

JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.

Read Article
European collaborative study of eosinophilic granulomatosis with polyangiitis (EGPA) Rx w/ RTX, mepolizumab or omalizumab (OMA). MEP > RTX > OMA. Mepolizumab was highly effective in GC‐dependent asthma. https://t.co/fi8pjnJO03

Dr. John Cush RheumNow ( View Tweet)

Oct 06, 2020
Swedish population study of psoriasis pts Rx w/ secukinumab (848) or ustekinumab (1107) showed slightly more respiratory infx & UTI (HR 1.22), w/ no difference in hospital treated severe respiratory, UTI (HR 0.96) or candidiasis (HR 1.80) https://t.co/yIRubED6VX

Dr. John Cush RheumNow ( View Tweet)

Oct 06, 2020
Danish comparison of 15K RA, 301K Diabetes adn 75K gen population; RA assoc w/ increased risk of CHF (HR 1.51), MI (HR 1.58), stroke (HR 1.22) vs gen. population; but RA had 20-40% lower CHF/MI/CVA than diabetes pts (who had highest 10 yr mortality).

Dr. John Cush RheumNow ( View Tweet)

Oct 02, 2020

Slow Lung Decline Typical in Systemic Sclerosis

Sep 30, 2020

The interstitial lung disease that develops in a subset of patients with systemic sclerosis tends to be heterogeneous, with the majority of patients experiencing a slow pattern of decline in lung function, analysis of outcomes in the European Scleroderma Trials and Research (EUSTAR) database

Read Article
The RheumNow Podcast is up! Cardiovascular Risk in Psoriatic Disease, Higher COVID rates in young adults, Reimbursements for Rheumatologists and more.

Dr. John Cush RheumNow ( View Tweet)

Sep 27, 2020
High-risk coronary plaques (LRNC) assessed by Coronary CT scores in 209 biologic naive Psoriasis pts. LNRC correlated w/ Framingham risk & Dz activity.

Dr. John Cush RheumNow ( View Tweet)

Sep 25, 2020

RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)

Sep 24, 2020

Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.

Read Article

Ustekinumab Early Risk for Cardiovascular Events

Sep 23, 2020

JAMA Dermatology reports a claims-based, case-time-controlled French study of 9290 psoriasis patients suggesting that ustekinumab initiation may be associated with an increased risk of acute coronary syndrome or stroke in high risk cardiovascular patients.

Read Article
Cluster analysis of 168 antiphospholipid pts shows that having arterial thromboses and cardiovascular risk factors was associated with mortality and poorest prognosis in APS. https://t.co/Nb7lZNu4jT

Dr. John Cush RheumNow ( View Tweet)

Sep 23, 2020
Outcomes survey of 229 relapsing polychondritis patients shows that 59% had auricular-onset (AO) and 21% had respiratory -onset (RO), 20% w/ miscellaneous-onset (MO- eye MSK CNS).

Dr. John Cush RheumNow ( View Tweet)

Sep 22, 2020

DMARDs for Early Rheumatoid Arthritis Have Cardiovascular Benefits

Sep 21, 2020

Patients with RA have up to a three-fold increased risk of mortality versus the general population, largely due to an increased incidence of premature CVD, such as atherosclerosis and heart failure. This excess risk is as high as that of patients with major CVD risk factors such as type 2

Read Article

RheumNow Podcast – Lupus Delights (9.18.20)

Sep 18, 2020

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

Read Article
Danish matched (1:4) cohort study shows COVID-19 pts taking NSAIDs had no greater risk of mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy; study included 9,236 COVID PCR-positive & 2.7% were on NSAIDs https://t.co/

Dr. John Cush RheumNow ( View Tweet)

Sep 15, 2020
ILD studied in 679 inflammatory idiopathic myositis (IIM) pts; 508 had ILD (found in 93% amyopathic DM, 74% DM & 55% PM). Prevalence of of ILD was higher with antisynthetase Ab + and MDA-5 Ab +.

Dr. John Cush RheumNow ( View Tweet)

Sep 14, 2020

Comorbidities Impact Disease Activity in Spondyloarthritis

Sep 13, 2020

An analysis of a large population-based cohort of axial spondyloarthritis (axSpA) patients shows that comorbidities are common and are associated with higher disease activity and higher levels of functional impairment.

Read Article
296 women with HTN during pregnancy (half/147 NSAID-exposed) - NSAID use was not associated with a significant change in BP (vs no NSAID) and there was no added need to start or increase BP meds in those on NSAIDS. https://t.co/g56xgQEPjr

Dr. John Cush RheumNow ( View Tweet)

Sep 09, 2020
×